NYGC Core Faculty Member Dan Landau, MD, PhD, who holds a joint appointment as Assistant Professor of Medicine in the Division of Hematology and Medical Oncology and the Department of Physiology and Biophysics at Weill Cornell Medicine.
Improving liquid biopsy, the emerging science which allows for early detection of cancer through the measurement of tumor DNA in a patient’s blood, is a key focus of the research team led by NYGC Core Faculty Member Dan Landau, MD, PhD, who holds a joint appointment as Assistant Professor of Medicine in the Division of Hematology and Medical Oncology and the Department of Physiology and Biophysics at Weill Cornell Medicine. Increasingly, a liquid biopsy approach is being used as an alternate diagnostic tool to patient imaging scans, which can be inconclusive, or tumor biopsies, which are invasive.
In July, in support the lab’s work in this area, The Mark Foundation for Cancer Research selected Dr. Landau as the inaugural recipient of its new ASPIRE (Accelerating Scientific Platforms and Innovative Research) Award. The lab’s award-winning project is focused on developing a more highly sensitive platform for liquid biopsy, seeking to overcome current barriers to accurately diagnosing cancer when tumors are very small and only minute amounts of tumor DNA are available in the quantities of blood that can be taken from a patient. Read more about Dr. Landau’s award-winning project here.
